Anti-Human Insulin Receptor Substrate-1 (IRS-1) Antibody

Leinco Technologies
Product Code: LEI-I-465
Product Group: Primary Antibodies
CodeSizePrice
LEI-I-465-20ug20 ug£199.00
Quantity:
LEI-I-465-0.1mg0.1 mg£591.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Images

1 / 1

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:I-482
Long Description:
Following tyrosine phosphorylation, the insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) can form a protein scaffolding for the assembly of a host of Src homology 2 (SH2) domain-containing proteins.1 IRS-1 tyrosine phosphorylation can occur through the activity of several cytokine and growth factor receptors such as interleukin (IL)-4, IL-9, interferon-α, in addition to the insulin and insulin-like growth factor 1 receptors.2 The scaffolding provided by IRS-1 and IRS-2 is necessary for insulin signal transduction across the cell membrane. IRS-1 tyrosine phosphorylation, and thus formation of the IRS scaffolding is inhibited by tumor necrosis factor (TNF), and this inhibition can itself be blocked by rapamycin, an inhibitor of the mammalian target of rapamycin (TOR)>3,4 TNF activity could also be blocked by inhibition of the Akt kinase and the PTEN tumor suppressor, suggesting that TNF impairs insulin signaling through IRS-1 by activation of the TOR signaling pathway.3
Target:
Insulin Receptor Substrate-1

References

1. Giovannone, B. et al. (2000) Diabetes Metab. Res. Rev. 16:434 2. Waters, SB. et al. (1996) Trends in Cell Biol. 6:1 3. Ozes, ON. et al. (2001) Proc. Natl. Acad. Sci. USA 98:4640 4. Shamji, AF. et al. (2003) Mol. Cell 12:271

Related Products

Product NameProduct CodeSupplier 
Insulin Receptor Substrate-1 Blocking PeptideLEI-I-482Leinco Technologies Summary Details